S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:BNTC

Benitec Biopharma - BNTC Stock Forecast, Price & News

$0.17
0.00 (0.00%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.16
$0.17
50-Day Range
$0.15
$0.35
52-Week Range
$0.13
$3.30
Volume
69,456 shs
Average Volume
778,895 shs
Market Capitalization
$4.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Benitec Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,276.7% Upside
$4.00 Price Target
Short Interest
Healthy
0.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

BNTC stock logo

About Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Stock News Headlines

Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Shares Surge 119%, to $1.62
Benitec Biopharma Discloses Q2 2022 Financial Results
/C O R R E C T I O N from Source -- Norra Metals Corp./
Benitec Biopharma Discloses Q1 2022 Financial Results
Benitec Biopharma Ltd. ADR
See More Headlines
Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Company Calendar

Today
12/09/2022
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTC
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+2,276.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,210,000.00
Pretax Margin
-25,008.22%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$0.35 per share

Miscellaneous

Free Float
27,542,000
Market Cap
$4.71 million
Optionable
Not Optionable
Beta
1.21

Key Executives

  • Dr. Jerel A. Banks M.D. (Age 47)
    Ph.D., Exec. Chairman & CEO
    Comp: $539.96k
  • Ms. Megan Joan Boston BComm (Age 50)
    CA, Dip., GAICD, Exec. Director
    Comp: $329.46k
  • Mr. Bryan Dulhunty
    Chief Financial Officer
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Craig Lewis
    Chief Medical Adviser
  • Dr. Claudia Kloth
    Sr. VP of Manufacturing













BNTC Stock - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings
or view top-rated stocks.

What is Benitec Biopharma's stock price forecast for 2023?

2 brokers have issued 1 year price objectives for Benitec Biopharma's stock. Their BNTC share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 2,257.1% from the stock's current price.
View analysts price targets for BNTC
or view top-rated stocks among Wall Street analysts.

How have BNTC shares performed in 2022?

Benitec Biopharma's stock was trading at $2.62 at the start of the year. Since then, BNTC stock has decreased by 93.5% and is now trading at $0.1697.
View the best growth stocks for 2022 here
.

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 165,200 shares, a decline of 50.6% from the October 31st total of 334,500 shares. Based on an average trading volume of 599,400 shares, the days-to-cover ratio is presently 0.3 days.
View Benitec Biopharma's Short Interest
.

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our BNTC earnings forecast
.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.02%), Empery Asset Management LP (2.85%), Altium Capital Management LP (2.55%), Cantor Fitzgerald L. P. (0.48%), Renaissance Technologies LLC (0.47%) and Group One Trading L.P. (0.00%).
View institutional ownership trends
.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $0.17.

How much money does Benitec Biopharma make?

Benitec Biopharma (NASDAQ:BNTC) has a market capitalization of $4.75 million and generates $70,000.00 in revenue each year. The biotechnology company earns $-18,210,000.00 in net income (profit) each year or ($119.48) on an earnings per share basis.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The official website for the company is www.benitec.com. The biotechnology company can be reached via phone at 510-780-0819, via email at jmorakis@mgroupsc.com, or via fax at 61 (0)3 9966-9923.

This page (NASDAQ:BNTC) was last updated on 12/9/2022 by MarketBeat.com Staff